{"created":"2023-06-19T07:24:57.750143+00:00","id":12166,"links":{},"metadata":{"_buckets":{"deposit":"40fe9689-b5c9-4f52-810b-c88c2ede9bf7"},"_deposit":{"created_by":5,"id":"12166","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"12166"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00012166","sets":["147:197"]},"author_link":["17964","17151","8903","17874","17303","17150"],"item_1_alternative_title_5":{"attribute_name":"論文名よみ","attribute_value_mlt":[{"subitem_alternative_title":"〓"}]},"item_1_biblio_info_14":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2001-06-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"48","bibliographicPageStart":"37","bibliographicVolumeNumber":"50","bibliographic_titles":[{"bibliographic_title":"岐阜藥科大學紀要"},{"bibliographic_title":"The annual proceedings of Gifu College of Pharmacy","bibliographic_titleLang":"en"}]}]},"item_1_creator_6":{"attribute_name":"著者名(日)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"丹羽, 学"}],"nameIdentifiers":[{"nameIdentifier":"17150","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永井, 博弌"}],"nameIdentifiers":[{"nameIdentifier":"17964","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_7":{"attribute_name":"著者名よみ","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ニワ, サトル"}],"nameIdentifiers":[{"nameIdentifier":"17151","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"ナガイ, ヒロイチ"}],"nameIdentifiers":[{"nameIdentifier":"17874","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_8":{"attribute_name":"著者名(英)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NIWA, Satoru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"17303","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NAGAI, Hiroichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"8903","nameIdentifierScheme":"WEKO"}]}]},"item_1_description_1":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P(論文)","subitem_description_type":"Other"}]},"item_1_description_11":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"レチノイドは細胞内の特異的レセプターと結合し,各種遺伝子の発現を調節することにより,細胞の分化,増殖および抗炎症作用など,種々の生理活性を示すことが多数報告されている。本研究では,これらの欠点を補うべく新しく合成されたレチノイド誘導体である,4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid(Am-80)の免疫薬理学的作用について検討し,次いでその作用機序についても合わせて検討した。Am-80は,マウスの2,4-dinitrofluorobenzene(DNFB)誘発接触性皮膚炎およびハプテン特異的1gE産生が強く見られるDNFB反復塗布によるマウス接触性皮膚炎において,耳介の腫脹を用量依存的に強く抑制した。また,Am-80はin vitroでの単核球からの抗原によるinterleukin-6(IL-6)ならびにinterferon-γ(IFN一γ)産生を抑制し,その抑制は転写レベルにおいて観察された。Am-80は,マウスのtypeIIコラーゲン誘発関節炎の発症を抑制し,C.Paruvum 前処置マウスのLipopolysaccharide(LPS)によるIL-6産生を抑制したが,ConcanavarinA(ConA)刺激したT細胞からのIFN-γおよびinteleukin-4(IL-4)産生には影響を及ぼさなかった。さらにAm-80は,ラットの実験的アレルギー性脳脊髄炎(EAE)の臨床症状および脊髄への細胞浸潤を用量依存的に抑制したが,投与中止によりEAEの再発が観察された。また,脊髄におけるIL-6mRNAの発現レベルにおいても同様に,投与中止後のIL-6mRNAの発現上昇が観察された。以上の結果から,Am-80は,リンパ球以外の細胞からのIL-6およびIFN-γの産生を選択的に抑制することにより,マウスおよびラットの接触性皮膚炎ならびに自己免疫疾患発症を抑制することが示唆された。これらの知見は,免疫性疾患における炎症性サイトカインの重要性ならびにレチノィド誘導体の治療薬としての有用性を示唆するものである。","subitem_description_type":"Other"}]},"item_1_description_12":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Retinoids have been reported to elicit a variety of biological activities such as cell differentiation, cell growth and anti-inflammatory effect, through the binding with specific intracellular receptors. In this study, we examined immunopharmacological effects of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) carbamoyl]benzoic acid (Am-80), a new retinoid-derivative, and its mechanism of actions. Am-80 inhibited ear swelling in a dose-dependent manner on 2,4-dinitrofluorobenzene (DNFB)-induced contact dermatitis and on contact dermatitis by the repeated applications of DNFB in mice. In addition, Am-80 inhibited production of inteleukin-6 (IL-6) and interferon-γ (IFN-γ) on mononuclear cells in vitro, and its inhibition was observed on a transcriptional level. Am-80 inhibited the elicitation of type II collagen-induced arthritis in mice. Am-80 inhibited lipopolysaccharide (LPS)-induced IL-6 production in C. Parvum-pretreated mice, but not the production of IFN-γ or IL-4 in T cells stimulated with concanavarin A (Con A) in vitro. Am-80 diminished clinical symptoms and infiltration of inflammatory cells into the spinal code on experimental allergic encephalomyelitis (EAE)-induced rats. However, after stopping administration, EAE recurred in DA rats treated with AM-80. Furthermore, the expressional level of IL-6 mRNA was diminished during the administration of Am-80,but provoked as soon as it was stopped. Therefore, Am-80 cured mice contact dermatitis, arthritis and rat EAE through the selective inhibition of IL-6 and IFN-γ secreted from inflammatory cells except for T cells. This evidence may suggest the importance of inflammatory cytokines and the usefulness of retinoid derivatives in immune disorders.","subitem_description_type":"Other"}]},"item_1_source_id_13":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AN00053514","subitem_source_identifier_type":"NCID"}]},"item_1_text_10":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Discovery Biology Group, Research Division, Tsukuba Research Institute, Novartis Pharma K.K./Laboratory of Pharmacology, Gifu Pharmaceutical University"}]},"item_1_text_9":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"ノバルティス・ファーマ株式会社筑波研究所 創薬生物グループ/岐阜薬科大学"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2001-06-30"}],"displaytype":"detail","filename":"KJ00000074071.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"url":"https://gifu-pu.repo.nii.ac.jp/record/12166/files/KJ00000074071.pdf"},"version_id":"1e2b2aed-7175-453a-8d7b-bebca01d20b0"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<総説>レチノイド誘導体の免疫薬理学的研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<総説>レチノイド誘導体の免疫薬理学的研究"},{"subitem_title":"<Review>Immunopharmacological study of Retinoid Derivatives","subitem_title_language":"en"}]},"item_type_id":"1","owner":"5","path":["197"],"pubdate":{"attribute_name":"公開日","attribute_value":"2001-06-30"},"publish_date":"2001-06-30","publish_status":"0","recid":"12166","relation_version_is_last":true,"title":["<総説>レチノイド誘導体の免疫薬理学的研究"],"weko_creator_id":"5","weko_shared_id":5},"updated":"2023-06-19T08:47:02.899746+00:00"}